Similar to the above results, the rates of MAOs were significantly higher in patients with penetrating type disease, CRP ≥ 0.5 mg/dL, and Alb < 3.8 g/dL at week 24 (Table 3, Fig. 1c,d). This evidence concerns the gene ALB and glycogen storage disease VI.